Tagged with KoNECT

Korea With over 30 years of experience in public office working in public health and pharmaceutical policy, food and drug safety regulations, national health and welfare policy, and overseas missions as a civil servant, Dr Bae Byuongjun now serves as president of the Korea National Enterprise for Clinical Trials (KoNECT). In…

Korea Dr Bae Byuongjun, president of the Korea National Enterprise for Clinical Trials (KoNECT), outlines why Korea stands out in the APAC region as a top clinical trial destination, how clinical trials around COVID-19 treatments are progressing in Korea, the pandemic’s effect on trials for medicines in other indications, and how…

Korea Ten of the top contract research organizations (CROs) currently operating in South Korea, as selected by KoNECT, the Korea National Enterprise for Clinical Trials. Six domestic firms and four international operators make up the top 10.   Made with Visme Infographic Maker     To find out more about Korea’s…

Korea Syneos Health, established through a merger in 2017, has held a foothold in Korea through its legacy organisations for over 10 years. Sora Lee, general manager of Syneos Korea, provides her assessment of the impact of the merger. She also comments on Syneos Health’s MoU with KoNECT (Korea National Enterprise…

Korea Deborah Chee, President of KoNECT (Korea National Enterprise for Clinical Trials), discusses what it takes to build one of the world’s leading clinical trials ecosystems and highlights the importance of partnerships and collaborations between different stakeholders in Korea as a key factor in making it such a strategic destination for both…

Korea National Enterprise for Clinical Trials Korea had a late start, but is now one of the global hot spots for clinical trials. How would you sum up and explain this quick evolution? Clinical trials in Korea began in the 1990s, but at that time they were limited to either local studies for domestically developed compounds…